BioCardia

BioCardia Equity

The The Equity of BioCardia (BCDA) as of Nov 20, 2026 is 895,000.00 USD. In the previous year, The Equity was 837,000.00 USD — a change of 6.93% (higher).

Equity

895,000.00USD

YoY

6.93%

Last updated:

In 2025, BioCardia's equity was 895,000.00 USD, a 6.93% increase from the 837,000.00 USD equity in the previous year.

The BioCardia Equity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity
Date
Equity
Jan 1, 2018
3.79 M USD
Jan 1, 2019
2.37 M USD
Jan 1, 2020
19.18 M USD
Jan 1, 2021
10.38 M USD
Jan 1, 2022
4.89 M USD
Jan 1, 2023
-1.60 M USD
Jan 1, 2024
837,000.00 USD
Jan 1, 2025
895,000.00 USD
The BioCardia Equity history
YEAREquityYoY
895,000.00USD+6.93%
837,000.00USD-152.21%
-1.60 MUSD-132.77%
4.89 MUSD-52.85%
10.38 MUSD-45.90%
19.18 MUSD+709.11%
2.37 MUSD-37.50%
3.79 MUSD-65.91%
11.13 MUSD-45.95%
20.58 MUSD+48.44%
13.87 MUSD+2.38%
13.54 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

BioCardia Stock analysis

What does BioCardia do? BioCardia, Inc. generates revenue through its clinical-stage regenerative medicine portfolio, primarily focused on CardiAMP and CardiALLO cell therapies. The CardiAMP Cell Therapy System is in Phase III trials for ischemic systolic heart failure, targeting healthcare providers and clinical trial sponsors seeking advanced treatments for heart failure patients. CardiALLO, an allogeneic off-the-shelf mesenchymal stem cell product, is developed for broader therapeutic applications, appealing to hospitals and research institutions requiring ready-to-use regenerative solutions. The company also monetizes the Helix Biotherapeutic Delivery System and Morph Deflectable Guide and Sheaths Products, which serve as complementary tools for medical professionals during therapeutic procedures. CardiAMP and CardiALLO are positioned as innovative therapeutic candidates targeting heart failure and regenerative medicine segments, with CardiAMP advancing toward potential commercialization in late-stage trials. The Helix Biotherapeutic Delivery System and Morph Deflectable Guide and Sheaths Products cater to interventional cardiology and surgical markets, providing specialized equipment for clinicians. BioCardia's revenue streams are derived from partnerships with clinical trial sponsors and direct sales of medical devices to healthcare facilities, focusing on cardiovascular and regenerative medicine applications. The company's business model relies on developing and commercializing cell therapies and medical devices, with CardiAMP leading the portfolio in late-stage development. CardiALLO serves as a complementary allogeneic product, while the Helix and Morph products support procedural needs in cardiology. Revenue is anticipated from future commercialization of CardiAMP post-trial success and from ongoing sales of the Helix and Morph systems to medical institutions. BioCardia is one of the most popular companies on Eulerpool.

Equity Details

Analyzing BioCardia's Equity

BioCardia's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding BioCardia's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating BioCardia's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

BioCardia's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in BioCardia’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about BioCardia stock

The Equity of BioCardia is 895,000.00 USD in 2025.

The Equity of BioCardia changed from 837,000.00 USD to 895,000.00 USD, representing a 6.93% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of The Equity BioCardia since 2006 – with annual values, charts, and detailed analysis.

The Equity's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Equity's BioCardia historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — BioCardia

All Key Metrics — BioCardia